

SCIENTIFIC PROGRAM

SESSION LECTURE

No. 56

New Vaccines Development and Application

Room: 307B

Co-Chairs: Guizhen Wu



Xiangguo Qiu



Day 3 October 29th (Monday) 8:30 – 12:00

Time	Speaker	Title
8:30-9:00	Xiangguo Qiu <i>Head, Vaccine Development and Antiviral Therapy, Public Health Agency of Canada</i>	Pan-filovirus vaccines are 100% protective in Ebola and Marburg viruses challenged mice
9:00-9:30	Elena Burtseva <i>chief of influenza etiology and epidemiology laboratory, Russia</i>	Influenza vaccines in Russian Federation: experience and efficacy
9:30-10:00	Wenbo Xu <i>Chief of WPRO Reference Laboratory of Measles/Rubella, China</i>	Avian Influenza Surveillance: LPAI viruses and HPAI H5Nx virus in northern Eurasia (2016-2018)
10:00-10:30	Tea Break	
10:30-11:00	Dayan Wang <i>Director of Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, China CDC</i>	Challenges and strategies of influenza vaccine strain recommendation
11:00-11:30	Youchun Wang <i>National Institutes for Food and Drug Control (NIFDC), China</i>	Development and Quality Control of Vaccines in China



Guizhen Wu

Prof. Wu is a senior expert on public health emergencies and laboratory biosafety and a team leader to construct laboratory biosafety management system in China; the member of Asia Pacific Biosafety Association Executive Committee; the key group leader of National Key R&D Program of China "Biosafety key technology research and development"; the vice chairman of Laboratory Biosafety Expert Review Committee of National Health Commission, the editor-in-chief of Biosafety and Health.



Xiangguo Qiu

xiangguo.qiu@canada.ca

Dr. Qiu holds appointments as Senior Research Scientist at the Public Health Agency of Canada. Her research focuses on developing and testing vaccines and therapeutics especially antibody based treatment against filoviruses; pathogenesis and animal model development for emerging and reemerging BSL3 & 4 viruses. Dr. Qiu and her research have led to the antibody cocktail therapeutics known as ZMAb and ZMapp, which were compassionately used to treat Ebola virus-infected patients during the recent West African epidemic.



Elena Burtseva

elena-burtseva@yandex.ru

chief of influenza etiology and epidemiology laboratory, leader senior scientist, Ivanovsky Institute of Virology FSBI "National Research Center for Epidemiology and Microbiology named after honorary academician N.F. Gamaleya" of the Ministry of Health of the Russian Federation.



Wenbo Xu

wenbo_xu1@aliyun.com

Chief of WPRO Reference Laboratory of Measles/Rubella and acting chief of WPRO Reference Laboratory of Poliomyelitis, Deputy Director of National Institute for Viral Disease Control and Prevention, Chinese Centre for Disease Control and Prevention. As the measles/rubella and hand, foot and mouth disease (HFMD) laboratory leader, established Measles/Rubella and HFMD LabNetwork including National Measles Lab(NML), 31 provincial labs, and 331 prefectural labs, which played an important role in the progress of measles and rubella elimination and HFMD control in China.



Dayan Wang

wangdayan@ivdc.chinacdc.cn

Dr. Da-yan Wang is professor, director of Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, China CDC. She mainly engage in the surveillance of influenza virus in China and researches related to evolution of influenza virus, to provide scientific basis for risk assessment and the control strategy of influenza. Her area also includes the recommendation of WHO influenza vaccine.



Youchun Wang

wangyc@nifdc.org.cn

Professor Youchun Wang, from National Institutes for Food and Drug Control (NIFDC). He got Medical Degree (MD) on Epidemiology from Peking Medical University and PhD on Virology from University College London (UCL). He has mainly worked on hepatitis virus, HIV, HPV and emerging viruses and obtained several grants from Wellcome Trust, Ministry of Science and Technology, National Foundation of Natural Science, and others.